OR WAIT null SECS
In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies addresses what stakeholders should be thinking of in the data collection space moving forward.
Mikulaschek: DHTs and COAs are really important for the industry, the regulatory bodies have defined the need for that information. For regulatory submissions they are very, very interested in the data from the patient perspective of the therapies and what they do, so it's important that we capture that information. That's one. Number two, we need to make sure that capturing that information is not too much of a burden for the subjects or the sites, so we can make sure that we can continually have the consistency in the compliance to meet the protocol needs without burdening sites or patients.